Fosravuconazole is under clinical development by Eisai and currently in Phase III for Fungal Infections. According to GlobalData, Phase III drugs for Fungal Infections have a 53% phase transition ...
The incidence of fungal endophthalmitis primarily ... severity of the infection and response to treatment. It is important to emphasize that a team approach involving both the ophthalmologist ...